Search

Your search keyword '"Baigent, C."' showing total 531 results

Search Constraints

Start Over You searched for: Author "Baigent, C." Remove constraint Author: "Baigent, C."
531 results on '"Baigent, C."'

Search Results

1. ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy

2. ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy

3. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

4. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

5. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

6. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

7. ASCEND-Eye

8. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial

9. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease

10. ASCEND-Eye

11. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies

12. Impact of CKD on Household Income

14. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

15. Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

16. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial

17. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis

18. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

19. Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK

20. Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

21. Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study

22. Cost-effectiveness of statin therapy in categories of patients in the UK

24. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

25. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

26. Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy

27. Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors

28. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

29. 2019 ESC Guidelines for themanagement of patients with supraventricular tachycardia

30. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

31. P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data

32. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis The Task Force for the management of COVID-19 of the European Society of Cardiology

33. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

34. 2019 ESC Guidelines for themanagement of patients with supraventricular tachycardia

35. A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts

37. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

38. Conventional and genetic evidence on the association between adiposity and chronic kidney disease

39. Impact of the COVID-19 pandemic on admission rates for, and management of, acute coronary syndromes in England

40. 2019 ESC/EAS Guidelines for the management of dyslipidaemias

41. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

42. 2019 ESC Guidelines for themanagement of patients with supraventricular tachycardia

43. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

44. Pragmatic Trials — Need for ADAPTABLE Design

45. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

Catalog

Books, media, physical & digital resources